Engineered immune cells take aim at Hard-to-Treat lymphomas
NCT ID NCT06340737
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back after a short course of chemotherapy. The study aims to see if this approach is safe, feasible to manufacture, and effective in shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD22 chimeric antigen receptor (CAR) T cells
- What this could lead to
- If successful, this could lead to a new treatment option for patients with certain B cell lymphomas that have not responded to standard therapies, potentially offering a path to remission.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone and could cause significant side effects, including severe immune reactions. The manufacturing of the cells may also fail for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Stanford University
RECRUITINGPalo Alto, California, 94304, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Can a Triple-Drug combo wipe out Slow-Growing lymphomas?
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Can donor immune cells be engineered to fight blood cancer?
- Can a simple blood test spot lymphoma earlier?